Advertisement
Takeda Pharmaceutical Company Limited (TAK)
NYSE - Nasdaq Real Time Price. Currency in USD
Follow
As of 11:49AM EST. Market open.
| Previous Close | 13.44 |
| Open | 13.49 |
| Bid | 13.61 x 1100 |
| Ask | 13.62 x 1100 |
| Day's Range | 13.49 - 13.63 |
| 52 Week Range | 12.58 - 15.08 |
| Volume | |
| Avg. Volume | 1,725,773 |
| Market Cap | 43.212B |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | 23.10 |
| EPS (TTM) | 0.59 |
| Earnings Date | Jan 30, 2025 - Feb 03, 2025 |
| Forward Dividend & Yield | 0.58 (4.35%) |
| Ex-Dividend Date | Mar 27, 2024 |
| 1y Target Est | 2,483.89 |
GlobeNewswireHUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States, Europe and China — HONG KONG, SHANGHAI & FLORHAM PARK, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a milestone payment following the pricing approval and launch of FRUZA
Pharmaceutical TechnologyTakeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies
The companies have teamed up to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platforms.
FortuneWhy this major drugmaker no longer has an ‘IT department’
Gabriele Ricci, chief data and technology officer, has been reorganizing the technology function at Takeda Pharmaceutical.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.